FGF21 and obesity due to melanocortin 4 receptor deficiency: Its efficacy in humans promoted the interest in FGF21 as a promising therapeutic molecule for various metabolic diseases (e.g., obesity, type 2 diabetes, and non-alcoholic fatty liver disease).